Multicomponent polysaccharide–protein bioconjugation in the development of antibacterial glycoconjugate vaccine candidates† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc05467j

• Published in: Chemical science (Cambridge) Vol. 9; no. 9; pp. 2581 - 2588
• Main Authors: Méndez, Yanira, Chang, Janoi, Humpierre, Ana R., Zanuy, Abel, Garrido, Raine, Vasco, Aldrin V., Pedroso, Jessy, Santana, Darielys, Rodríguez, Laura M., García-Rivera, Dagmar, Valdés, Yury, Vérez-Bencomo, Vicente, Rivera, Daniel G.
• Format: Journal Article
• Language: English
• Published: Royal Society of Chemistry 19.01.2018
• Subjects: Chemistry
• ISSN: 2041-6520; 2041-6539
• DOI: 10.1039/c7sc05467j

A multicomponent reaction enables the one-pot assembly of immunogenic multivalent glycoconjugates. A new synthetic strategy for the development of multivalent antibacterial glycoconjugate vaccines is described. The approach comprises the utilization of an isocyanide-based multicomponent process for the conjugation of functionalized capsular polysaccharides of S. pneumoniae and S. Typhi to carrier proteins such as diphtheria and tetanus toxoids. For the first time, oxo- and carboxylic acid-functionalized polysaccharides could be either independently or simultaneously conjugated to immunogenic proteins by means of the Ugi-multicomponent reaction, thus leading to mono- or multivalent unimolecular glycoconjugates as vaccine candidates. Despite the high molecular weight of the two or three reacting biomolecules, the multicomponent bioconjugation proved highly efficient and reproducible. The Ugi-derived glycoconjugates showed notable antigenicity and elicited good titers of functional specific antibodies. To our knowledge, this is the only bioconjugation method that enables the incorporation of two different polysaccharidic antigens to a carrier protein in a single step. Applications in the field of self-adjuvanting, eventually anticancer, multicomponent vaccines are foreseeable.